E-therapeutics Appoints Non-Executive Chair
This article was originally published in Scrip
Executive Summary
E-therapeutics has appointed Iain Ross to its board of directors as non-executive chair and acting chair Malcolm Young has stepped down, continuing his role as CEO. Ross brings more than 35 years' experience to e-Therapeutics and is currently non-executive director Anatara LifeSciences Ltd., non-executive chair of Premier Veterinary Group plc. and Biomer Technology Ltd. Previously, Ross held roles in Sandoz, Hoffman La Roche and Celltech Group plc., where he was CEO.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.